| 18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors K London, C Stege, S Cross, E Onikul, N Graf, G Kaspers, L Dalla-Pozza, ... Pediatric radiology 42, 418-430, 2012 | 67 | 2012 |
| Carfilzomib for relapsed and refractory multiple myeloma K Groen, N Van De Donk, CAM Stege, S Zweegman, IS Nijhof Cancer management and research, 2663-2675, 2019 | 66 | 2019 |
| CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience KA Frerichs, NA Nagy, PL Lindenbergh, P Bosman, J Marin Soto, ... Expert Review of Clinical Immunology 14 (3), 197-206, 2018 | 52 | 2018 |
| Resistance mechanisms towards CD38− directed antibody therapy in multiple myeloma LE Franssen, CAM Stege, S Zweegman, NWCJ van de Donk, IS Nijhof Journal of Clinical Medicine 9 (4), 1195, 2020 | 39 | 2020 |
| Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 study CAM Stege, K Nasserinejad, E Van der Spek, YM Bilgin, A Kentos, ... Journal of Clinical Oncology 39 (25), 2758-2767, 2021 | 31 | 2021 |
| Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma H Mian, SJ Grant, M Engelhardt, C Pawlyn, S Bringhen, S Zweegman, ... Journal of geriatric oncology 11 (5), 764-768, 2020 | 30 | 2020 |
| Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for … S Zweegman, CAM Stege, E Haukas, FH Schjesvold, MD Levin, A Waage, ... haematologica 105 (12), 2879, 2020 | 29 | 2020 |
| Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities CAM Stege, B van der Holt, AG Dinmohamed, P Sonneveld, MD Levin, ... Leukemia 34 (7), 1964-1966, 2020 | 26 | 2020 |
| Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until … LK Nielsen, C Stege, B Lissenberg-Witte, B Van Der Holt, UH Mellqvist, ... haematologica 105 (6), 1650, 2020 | 23 | 2020 |
| Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (Ixa Dara dex) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients; results of the … CAM Stege, K Nasserinejad, E van der Spek, RJW Van Kampen, ... Blood 134, 695, 2019 | 18 | 2019 |
| Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients; first interim safety … CAM Stege, K Nasserinejad, MD Levin, N Thielen, SK Klein, I Ludwig, ... Blood 132, 596, 2018 | 18 | 2018 |
| Geriatric impairments and low muscle mass are associated with treatment discontinuation and overall survival in newly diagnosed non-transplant eligible multiple myeloma … CAM Stege, K Nasserinejad, MD Levin, SK Klein, E De Waal, C Eeltink, ... Blood 132, 1889, 2018 | 12 | 2018 |
| Cerebrospinal fluid penetrance of daratumumab in leptomeningeal multiple myeloma M Zajec, KA Frerichs, MM van Duijn, IS Nijhof, CAM Stege, ... Hemasphere 4 (4), e413, 2020 | 9 | 2020 |
| Feasibility and efficacy of dose adjusted melphalan-prednisone-bortezomib (mpv) in elderly patients≥ 75 years of age with newly diagnosed multiple myeloma; the non-randomised … S Zweegman, MD Levin, SK Klein, EGM De Waal, CM Eeltink, PF Ypma, ... Blood 128 (22), 3305, 2016 | 7 | 2016 |
| Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL L Van Der Straten, CAM Stege, S Kersting, K Nasserinejad, J Dubois, ... Blood 142 (13), 1131-1142, 2023 | 6 | 2023 |
| Improving the identification of frail elderly newly diagnosed multiple myeloma patients CAM Stege, K Nasserinejad, SK Klein, GJ Timmers, M Hoogendoorn, ... Leukemia 35 (9), 2715-2719, 2021 | 6 | 2021 |
| Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible … S Zweegman, FH Schjesvold, B van der Holt, MD Levin, CAM Stege, ... Blood 132, 800, 2018 | 6 | 2018 |
| Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible … S Zweegman, B van der Holt, FH Schjesvold, MD Levin, CAM Stege, ... Blood 130, 433, 2017 | 5 | 2017 |
| Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial K Groen, CAM Stege, K Nasserinejad, K de Heer, RJW van Kampen, ... EClinicalMedicine 63, 2023 | 4 | 2023 |
| Ixazomib, daratumumab and low dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma (NDMM); results of induction treatment of the phase II HOVON … K Groen, CAM Stege, K Nasserinejad, K de Heer, RJW Van Kampen, ... Blood 138, 80, 2021 | 4 | 2021 |
